NEW YORK, March 05, 2018 -- Rosen Law Firm, a global investor rights law firm, announces that a lawsuit has been filed on behalf of purchasers of the securities of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) from May 8, 2017 through January 30, 2018, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Bellicum investors under the federal securities laws.
To join the Bellicum class action, go to http://rosenlegal.com/cases-1286.html or call Phillip Kim, Esq. or Zachary Halper, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) a substantial undisclosed risk of encephalopathy was associated with Bellicum’s lead product candidate, BPX-501; and (2) as a result, Bellicum’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 9, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1286.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Zachary Halper, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Zachary Halper, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Adobe Names Anil Chakravarthy CEO as AI Push Accelerates
Audi, SAIC Launch China Innovation Hub for New AUDI Models
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns
Lynas Rare Earths Shares Rise After Takeover Talks Revealed
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up
Anthropic Nears $15 Billion Credit Deal Ahead of IPO
ByteDance Secures $29.6 Billion Loan to Boost AI Investment
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks
France Targets Shein, Temu With Fast-Fashion Fees
OpenAI Rejects Apple Trade Secret Theft Claims
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 



